Shares of MyoKardia Inc. (MYOK) are soaring over 80% in pre-market today, after the company announced positive topline data from its Phase 3 pivotal EXPLORER-HCM clinical trial of mavacamten for the treatment of patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM).
from RTT - Before the Bell https://ift.tt/2Wp78up
via IFTTT
No comments:
Post a Comment